Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

KMT2A (Lysine Methyltransferase 2A)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

KMT2A rearrangement	Acute Lymphocytic Leukemia	KMT2A rearrangement	Acute Lymphocytic Leukemia	CEP-701 Sensitive: B - Late Trials CEP-701 Sensitive : B	CEP-701 Sensitive: B - Late Trials CEP-701 Sensitive : B
KMT2A rearrangement	Acute Myelogenous Leukemia	KMT2A rearrangement	Acute Myelogenous Leukemia	revumenib Sensitive: B - Late Trials revumenib Sensitive : B	revumenib Sensitive: B - Late Trials revumenib Sensitive : B
KMT2A rearrangement	Acute Myelogenous Leukemia	KMT2A rearrangement	Acute Myelogenous Leukemia	DSP-5336 Sensitive: B - Late Trials DSP-5336 Sensitive : B	DSP-5336 Sensitive: B - Late Trials DSP-5336 Sensitive : B
KMT2A rearrangement	Acute Myelogenous Leukemia	KMT2A rearrangement	Acute Myelogenous Leukemia	ziftomenib Sensitive: C2 – Inclusion Criteria ziftomenib Sensitive : C2	ziftomenib Sensitive: C2 – Inclusion Criteria ziftomenib Sensitive : C2
KMT2A rearrangement	Acute Myelogenous Leukemia	KMT2A rearrangement	Acute Myelogenous Leukemia	venetoclax + revumenib Sensitive: C2 – Inclusion Criteria venetoclax + revumenib Sensitive : C2	venetoclax + revumenib Sensitive: C2 – Inclusion Criteria venetoclax + revumenib Sensitive : C2
KMT2A-PTD	Acute Myelogenous Leukemia	KMT2A-PTD	Acute Myelogenous Leukemia	cytarabine + decitabine + vorinostat Sensitive: C3 – Early Trials cytarabine + decitabine + vorinostat Sensitive : C3	cytarabine + decitabine + vorinostat Sensitive: C3 – Early Trials cytarabine + decitabine + vorinostat Sensitive : C3
KMT2A mutation	Solid Tumor	KMT2A mutation	Solid Tumor	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KMT2A rearrangement	Acute Myelogenous Leukemia	KMT2A rearrangement	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: C3 – Early Trials gemtuzumab ozogamicin Sensitive : C3	gemtuzumab ozogamicin Sensitive: C3 – Early Trials gemtuzumab ozogamicin Sensitive : C3
KMT2A rearrangement	Childhood B Acute Lymphoblastic Leukemia	KMT2A rearrangement	Childhood B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3
KMT2A rearrangement + CD19 positive	Acute Lymphocytic Leukemia	KMT2A rearrangement + CD19 positive	Acute Lymphocytic Leukemia	tisagenlecleucel-T Sensitive: C3 – Early Trials tisagenlecleucel-T Sensitive : C3	tisagenlecleucel-T Sensitive: C3 – Early Trials tisagenlecleucel-T Sensitive : C3
KMT2A rearrangement + CD19 positive	Acute Lymphocytic Leukemia	KMT2A rearrangement + CD19 positive	Acute Lymphocytic Leukemia	CD19-targeted CAR-T immunotherapy Sensitive: C3 – Early Trials CD19-targeted CAR-T immunotherapy Sensitive : C3	CD19-targeted CAR-T immunotherapy Sensitive: C3 – Early Trials CD19-targeted CAR-T immunotherapy Sensitive : C3
KMT2A rearrangement	Acute Myelogenous Leukemia	KMT2A rearrangement	Acute Myelogenous Leukemia	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3